347 related articles for article (PubMed ID: 29447484)
61. Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells.
Zimmermann J; van Haren SD; Diray-Arce J; Adriawan IR; Wørzner K; Krog RT; Guleed S; Hu T; Mortensen R; Dietrich J; Solbak SMØ; Levy O; Christensen D; Pedersen GK
NPJ Vaccines; 2023 Dec; 8(1):189. PubMed ID: 38135685
[TBL] [Abstract][Full Text] [Related]
62. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.
Wang D; Christopher ME; Nagata LP; Zabielski MA; Li H; Wong JP; Samuel J
J Clin Virol; 2004 Dec; 31 Suppl 1():S99-106. PubMed ID: 15567101
[TBL] [Abstract][Full Text] [Related]
63. H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice.
Qin T; Yin Y; Huang L; Yu Q; Yang Q
Clin Vaccine Immunol; 2015 Apr; 22(4):421-9. PubMed ID: 25673304
[TBL] [Abstract][Full Text] [Related]
64. Engineering of an inhalable DDA/TDB liposomal adjuvant: a quality-by-design approach towards optimization of the spray drying process.
Ingvarsson PT; Yang M; Mulvad H; Nielsen HM; Rantanen J; Foged C
Pharm Res; 2013 Nov; 30(11):2772-84. PubMed ID: 23794038
[TBL] [Abstract][Full Text] [Related]
65. Electrostatic parameters of cationic liposomes commonly used for gene delivery as determined by 4-heptadecyl-7-hydroxycoumarin.
Zuidam NJ; Barenholz Y
Biochim Biophys Acta; 1997 Oct; 1329(2):211-22. PubMed ID: 9371413
[TBL] [Abstract][Full Text] [Related]
66. Formulation in DDA-MPLA-TDB Liposome Enhances the Immunogenicity and Protective Efficacy of a DNA Vaccine against
Tian M; Zhou Z; Tan S; Fan X; Li L; Ullah N
Front Immunol; 2018; 9():310. PubMed ID: 29535714
[TBL] [Abstract][Full Text] [Related]
67. Gel Phase 1,2-Distearoyl-
Norling K; Bernasconi V; Agmo Hernández V; Parveen N; Edwards K; Lycke NY; Höök F; Bally M
ACS Infect Dis; 2019 Nov; 5(11):1867-1878. PubMed ID: 31498993
[TBL] [Abstract][Full Text] [Related]
68. Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity.
Mai Y; Guo J; Zhao Y; Ma S; Hou Y; Yang J
Cell Immunol; 2020 Aug; 354():104143. PubMed ID: 32563850
[TBL] [Abstract][Full Text] [Related]
69. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.
Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B
Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736
[TBL] [Abstract][Full Text] [Related]
70. Lipoplexes formulation and optimisation: in vitro transfection studies reveal no correlation with in vivo vaccination studies.
McNeil SE; Vangala A; Bramwell VW; Hanson PJ; Perrie Y
Curr Drug Deliv; 2010 Apr; 7(2):175-87. PubMed ID: 20158478
[TBL] [Abstract][Full Text] [Related]
71. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
72. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice.
Ninomiya A; Ogasawara K; Kajino K; Takada A; Kida H
Vaccine; 2002 Aug; 20(25-26):3123-9. PubMed ID: 12163263
[TBL] [Abstract][Full Text] [Related]
73. Liposomes enhance the immunogenicity of reconstituted influenza virus A/PR/8 envelopes and the formation of protective antibody by influenza virus A/Sichuan/87 (H3N2) surface antigen.
Gregoriadis G; Tan L; Ben-Ahmeida ET; Jennings R
Vaccine; 1992; 10(11):747-53. PubMed ID: 1441730
[TBL] [Abstract][Full Text] [Related]
74. A Lipopolysaccharide from Pantoea Agglomerans Is a Promising Adjuvant for Sublingual Vaccines to Induce Systemic and Mucosal Immune Responses in Mice via TLR4 Pathway.
Fukasaka M; Asari D; Kiyotoh E; Okazaki A; Gomi Y; Tanimoto T; Takeuchi O; Akira S; Hori M
PLoS One; 2015; 10(5):e0126849. PubMed ID: 25978818
[TBL] [Abstract][Full Text] [Related]
75. Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response.
Kaur R; Bramwell VW; Kirby DJ; Perrie Y
J Control Release; 2012 Dec; 164(3):331-7. PubMed ID: 22800572
[TBL] [Abstract][Full Text] [Related]
76. Preparation, characterisation and entrapment of a non-glycosidic threitol ceramide into liposomes for presentation to invariant natural killer T cells.
Kaur R; Chen J; Dawoodji A; Cerundolo V; Garcia-Diaz YR; Wojno J; Cox LR; Besra GS; Moghaddam B; Perrie Y
J Pharm Sci; 2011 Jul; 100(7):2724-33. PubMed ID: 21283989
[TBL] [Abstract][Full Text] [Related]
77. Adsorption of protein antigen to the cationic liposome adjuvant CAF®01 is required for induction of Th1 and Th17 responses but not for antibody induction.
Wørzner K; Hvannastein J; Schmidt ST; Foged C; Rosenkrands I; Pedersen GK; Christensen D
Eur J Pharm Biopharm; 2021 Aug; 165():293-305. PubMed ID: 34044110
[TBL] [Abstract][Full Text] [Related]
78. Role of interleukin-6 in antigen-specific mucosal immunoglobulin A induction by cationic liposomes.
Tada R; Hidaka A; Tanazawa Y; Ohmi A; Muto S; Ogasawara M; Saito M; Ohshima A; Iwase N; Honjo E; Kiyono H; Kunisawa J; Negishi Y
Int Immunopharmacol; 2021 Dec; 101(Pt A):108280. PubMed ID: 34710845
[TBL] [Abstract][Full Text] [Related]
79. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522.
Rose F; Wern JE; Gavins F; Andersen P; Follmann F; Foged C
J Control Release; 2018 Feb; 271():88-97. PubMed ID: 29217176
[TBL] [Abstract][Full Text] [Related]
80. A Liposome-Based Adjuvant Containing Two Delivery Systems with the Ability to Induce Mucosal Immunoglobulin A Following a Parenteral Immunization.
Christensen D; Bøllehuus Hansen L; Leboux R; Jiskoot W; Christensen JP; Andersen P; Dietrich J
ACS Nano; 2019 Feb; 13(2):1116-1126. PubMed ID: 30609354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
